good points most here dont realize that lovenox was standard of care 10 years
tobe no clinically significant difference is huge.
for it to exceed will be super huge.
normally drug companies do not compare their drug to the newest standard of care
they pick a old obsolete drug.
the fact they used enoxaparin and missed by a fraction of a % is a train wreck for share price today
but i would say 90% chance approval longer term
its broken until further notice.
it broke all the lows of past 2 years.
nothing matters when 50-70% of shareholders are under water except that most are
institutional and can handle 10-20 million slam if they want can sit back for another 3-5 years.
and a pro that buys bio-tech never buys more than they can afford 100% loss.
and always considers need 3-10 years for a home-run.
that and andexanet is a real drug with real potential.
i will buy when free fall is over when ever that is??
it does matter. i subscrib to NEJOM and the article was positive to the point i thought it was already approved.
as soon as a saw the company was public i came here and saw the carnage. use these minimally is b/c non-reversible
reminds me of vphm which was killed b/c one drug was turned down but had another drug (vancomycin) that was a cash printing machine.
this Xa and FXa are huge 3 out of 4 of your parents and grandparents will be on these in future.
the biggest and HUGE reason doctors and pharmacist(myself) dont use or use minimally are b/c non-reversible . xarelto poster child for lawsuits
andexanet changes that.
once this stops free fall and bases its a long term buy.
they could do current rev. cap in sales in one year which incr. mkt cap to 10 billion potential 10 bagger here.